Previous 10 | Next 10 |
Meridian Bioscience ([[VIVO]] -8.0%) updates its communication regarding the withdrawal of its application for Emergency Use Authorization ((EUA)) with the U.S. FDA for the SARS-CoV-2 molecular diagnostic test on its Revogene platform.The FDA has now clarified that Meridian will not...
CINCINNATI, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, updated its communication regarding the withdrawal of its application for Emergency Use Authorization (EUA) with the U.S. Food a...
CINCINNATI, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided a further update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (F...
Stock market indices stand to finish mixed after a holiday-shortened week where Congressional hearings around GameStop (GME) dominated headlines. The Nasdaq (COMP) may eke out a small gain for the week, while the S&P 500 (SP500) is down about 0.8% at the time of this writing. Dow Industri...
Quidel Corporation ([[QDEL]] -10.9%) has failed to meet the consensus revenue estimates in Q4 2020 despite the surging pandemic driving a ~80.6% YoY sequential growth in revenue from COVID-19 products.Today, the stock is leading a broader selloff among COVID-19 test makers after Evercore ISI ...
While small-cap stocks are usually considered relatively risky investments, some small-cap stocks hold explosive growth potential. Because most popular stocks are now trading at lofty valuations, it could be wise to bet on small-cap players like Atkore International Group (ATKR), Meridian Bio...
Meridian Bioscience (VIVO) has seen its stock soar on the back of rising demand for COVID tests. While testing should continue for some time, is the growth already factored into the price? Or will the rally continue? Read more to find out. Meridian Bioscience ( VIVO ) has soared over t...
The FDA late Feb. 12 requested that Meridian Bioscience (VIVO) provide additional information for an Emergency Use Authorization application for its SARS-CoV-2 molecular diagnostic test based on the Revogene platform.The company says it plans to send a response to the agency later today.Merid...
CINCINNATI, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided an update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for...
Two new breakout stocks for Week 6 of 2021 with better than 10% short-term upside potential. This past week three out of four stocks gained over 10% with VXRT gaining over 162% before pulling back midweek with average -2.96% portfolio declines to the close. 2021 MDA portfolio retu...
News, Short Squeeze, Breakout and More Instantly...
Meridian Bioscience Inc. Company Name:
VIVO Stock Symbol:
NASDAQ Market:
Meridian Bioscience Inc. Website:
The worldwide smartphone market has recently experienced a notable upturn in sales. October saw a 5% year-on-year growth, breaking a 27-...
Apple Inc. (NASDAQ:AAPL) has once again emerged as the most resilient smartphone maker in the world, reporting the slowest decline in iPhone shipme...
Net revenue for Q4 2022 was $7.1 million, a 15% increase from prior quarter. Net revenue for 2022 was $25.4 million, a 2% increase compared to 2021. Net losses have decreased by 21.2 million in 2022, a 30% decrease from the prior year. The Company signed a definitive agreemen...